Navigation Links
uniQure Initiates Phase I in Acute Intermittent Porphyria
Date:12/11/2012

AMSTERDAM, December 11, 2012 /PRNewswire/ --

uniQure B.V., a leader in the field of human gene therapy, today announced the start of its Phase I clinical trial in acute intermittent porphyria (AIP) with the treatment of the first patient. The study is conducted under the aegis of the AIPGENE consortium, a pan-European collaboration funded in part by the European Commission's Seventh Framework Program with the aim to develop a gene therapy for the treatment of AIP, a rare and devastating disease caused by mutations in the porphobilinogen deaminase gene (PBGD). AIP can be life-threatening and the long-term effects include irreversible nerve damage, liver cancer and kidney failure. uniQure was granted orphan drug designation for the treatment of AIP in 2009 from the European Medicines Agency.

"The start of the AIP Phase I study marks the first of four programs that will enter clinical trials over the next 12 months," says Jörn Aldag, CEO of uniQure.  "After AIP we expect clinical trials to be initiated in Parkinson's disease, hemophilia B, and Sanfilippo B. After many years of building and developing our capabilities and competencies, and the approval in November of Glybera for LPLD as the first gene therapy in the Western world, we are highly motivated to expedite the clinical development of our other advanced gene therapies."

About the AIP Phase I study

The Phase I will enroll eight patients with severe AIP at two centers: the Clinical University of Navarra, Pamplona, Spain, and the 12 de Octubre University Hospital,, Madrid, Spain. The study's primary objective is the assessment of safety and determination of the maximum tolerated dose.  Secondary objectives include tolerability of treatment, pharmacokinetics, changes in the levels of surrogate markers of activity including porphobilinogen (PBG) and delta-aminolevulinic acid (ALA), and assessment of symptom control, neuro-psychological changes and quality of life. All pa
'/>"/>

SOURCE uniQure B.V.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. uniQure Appoints Hans Christian Rohde Chief Commercial Officer
2. uniQure Licenses RNA Interference Technology to Advance Huntingtons Disease Program
3. Fate Therapeutics Initiates Phase 2 Clinical Study of ProHema for the Treatment of Hematologic Malignancies
4. The Acute Liver Failure Study Group Initiates Phase 2a Study of OCR-002 for Treatment of Acute Liver Failure after Acetaminophen Overdose
5. Isis Pharmaceuticals Initiates Phase 1b/2a Study Of ISIS-SMNRx In Patients With Spinal Muscular Atrophy
6. Isis Initiates Phase 2 Study Of ISIS-FXIRX In Patients Undergoing Knee Replacement Surgery
7. Synthetic Biologics Initiates Development of Monoclonal Antibodies for Treatment of Acinetobacter Infections
8. Healthpoint Biotherapeutics Initiates Phase III Study of Unique Investigational Cell-Based Therapy for Venous Leg Ulcers
9. New Jersey Health Foundation Initiates Program To Spur Innovative Research
10. Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for Discoid Lupus
11. ImmusanT Initiates Clinical Trials of Nexvax2 Therapeutic Vaccine for Celiac Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital (MGH), ... AMGN ) announced today that they have launched ... new therapeutic targets and develop novel therapies for ... affects millions worldwide. The MGH-Broad-Amgen collaboration brings together ...
(Date:1/15/2014)... an unprecedented effort to curb the spread of "superbugs" such as ... an advanced and portable UV germicidal lamp manufactured by MRSA-UV is ... In order to prevent EMS paramedics and transport patients ... Palm Beach Fire Rescue is the first in the ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium Research ... market intelligence, the United States ... device markets will expand moderately through 2022, with ... In particular, increasing interest in drug-eluting beads (DEBs) ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Superbugs No Longer Ride In Rescue Vehicles 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... Aug. 8, 2011 Insmed Incorporated (Nasdaq CM: INSM), a ... six-months ended June 30, 2011. Key Recent ... of data from the open-label phase 2 study of Arikace™ ... (CF) patients with Pseudomonas lung infections ...
... (NYSE Amex: ANX ) today reported financial results ... we head into the second half of the year, we ... into the U.S. market, should it be approved on or ... Brian M. Culley, Chief Executive Officer of ADVENTRX.  "Having a ...
Cached Medicine Technology:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011 2Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011 3Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011 4Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011 5Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011 6Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011 7Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011 8ADVENTRX Reports Second Quarter 2011 Financial Results 2ADVENTRX Reports Second Quarter 2011 Financial Results 3ADVENTRX Reports Second Quarter 2011 Financial Results 4ADVENTRX Reports Second Quarter 2011 Financial Results 5ADVENTRX Reports Second Quarter 2011 Financial Results 6ADVENTRX Reports Second Quarter 2011 Financial Results 7
(Date:4/23/2014)... New Rochelle, NY, April 23, 2014Men whose testosterone falls ... dysfunction and to be overweight and have heart disease ... designed to identify testosterone-deficient men for further testing and ... Journal of Men,s Health , a peer-reviewed publication from ... free on the Journal of Men,s Health ...
(Date:4/23/2014)... Fruits and vegetables are often displayed in the ... are also plenty of high-sugar foods. A new ... food is portrayed in children,s TV programmes as ... viewing, dietary habits and weight status. , Steingerdur ... food in the popular Swedish children,s TV show ...
(Date:4/23/2014)... Leisure Time Physical Activity on Mobility Limitation in Old ... the risk of mobility limitation in old age, whereas ... in a study which followed up 5,200 public sector ... the Gerontology Research Center in Finland and the Finnish ... often repetitive, wears the body and lasts for several ...
(Date:4/22/2014)... high school sport in the United States with 1 ... in the Center for Injury Research and Policy at ... describe the occurrence and distribution patterns of basketball-related injuries ... training setting among adolescents and teens. , The study, ... , examined data relating to adolescents 13-19 years of ...
(Date:4/22/2014)... Researchers at UT Southwestern Medical Center are making ... . , A team of physician-scientists at UT ... (a hormone with natural anti-depressant properties) works inside the ... treatment for depression in the form of a neuroprotective ... published online in April,s issue of Molecular Psychiatry, ...
Breaking Medicine News(10 mins):Health News:High-calorie and low-nutrient foods in kids' TV 2Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 3Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3
... - A protein crucial for the immune response appears to ... form of childhood leukemia called T-cell acute lymphoblastic leukemia (T-ALL). ... the study shows, opening a potential avenue to new drugs ... by Iannis Aifantis, PhD, associate professor of pathology and director ...
... visual evidence of blue-green algae, also known as cyanobacteria, ... present in lakes or reservoirs. In a newly published ... compounds were found almost every time cyanotoxins were found, ... toxins are present. "It is commonly believed that ...
... left partially paralysed found that their condition improved after they ... to research in the September issue of the European ... Ain Shams University in Cairo, Egypt, studied 60 patients with ... the brain - who had been left with mild to ...
... overall mortality from cancer is decreasing in the European Union, its ... 2002 to 2.5 million in 2008, says a special issue [1] ... of ECCO the European CanCer Organisation) on cancer prevention, published ... economic crisis threatens to affect cancer incidence in a number of ...
... In people with Alzheimer,s, the brain becomes riddled with clumps of ... appearing in the September 17th print issue of Cell ... (APP for short) that yields the prime ingredient in those plaques. ... whose job it is to convert iron from an unsafe form ...
... Doheny HealthDay Reporter , THURSDAY, Sept. 9 (HealthDay ... double for talented teenage athletes. They,re young, immortal, at the ... So when news hits that an apparently healthy, high ... of playing his or her favorite sport, millions of parents ...
Cached Medicine News:Health News:NYU Langone scientists find key pathway implicated in progression of childhood cancer 2Health News:If the water looks and smells bad, it may be toxic 2Health News:Brain stimulation can help partially paralyzed stroke patients regain use of their muscles 2Health News:Cancer deaths fall, but prevention still lags behind 2Health News:Cancer deaths fall, but prevention still lags behind 3Health News:Cancer deaths fall, but prevention still lags behind 4Health News:Cancer deaths fall, but prevention still lags behind 5Health News:Function found for Alzheimer's protein 2Health News:Clearing Kids for Sports Participation Sparks Conflicts 2Health News:Clearing Kids for Sports Participation Sparks Conflicts 3Health News:Clearing Kids for Sports Participation Sparks Conflicts 4Health News:Clearing Kids for Sports Participation Sparks Conflicts 5
The sterile cardiac blanket is utilized during surgical procedures that require access to the upper half of the body. Warms groin area while providing easy access to the area through a perforated ope...
2-ply material consisting of polyethylene film inner layer and non-woven outer layers....
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and ...
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and ...
Medicine Products: